{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9', 'Total carbon dioxide replaced with', 'Editorial changes to reflect the', 'bicarbonate', 'Table 14 List of', 'correct parameter', 'Clinical Laboratory', 'Bone marrow to confirm stringent', 'Tests', 'complete response by flow cytometry', 'Editorial changes to reflect IMWG', 'deleted and an additional footnote', 'criteria 2016.', 'included', '9.9.1 sBCMA Sample', 'Specific assay used for sample', 'Analysis', 'collection, i.e.', 'electrochemiluminescent', 'immunoassay deleted', '9.10 Evaluation of', 'Testing for evaluation of anti-cancer', 'Clarification to state this should', 'Anti-Cancer Activity', 'activity at 6 months included', 'be performed at the 6-month', 'timepoint.', 'Section 10.1', 'The sample size and hypothesis', 'Section updated to reflect revised', 'Hypothesis Testing', 'testing is updated to reflect a 2-arm', 'design and operating', 'study. Updated enrollment duration', 'characteristics based on', 'and number of evaluable participants', 'interactions with regulatory', 'for interim analysis.', 'agency.', 'Section 10.2 Sample', 'Included information on independent', 'Section updated to reflect revised', 'Size Determination', 'cohort for lyophilized configuration.', 'design and operating', 'characteristics based on', 'interactions with regulatory', 'agency.', 'Section 10.3 Sample', 'Updated IA futility stopping rules', 'Section updated to reflect revised', 'Size Sensitivity', 'design and operating', 'characteristics based on', 'Section 10.5.9.1', 'Futility Stopping Rule', 'interactions with regulatory', 'based on Group', 'agency.', 'Sequential Design', 'Section 10.4', 'Safety population has been replaced', 'Population for Analysis', 'with ITT population as a primary', 'Section 10.5.1 Efficacy', 'population of analysis of efficacy', 'Analysis', 'data and safety population updated', 'to be used for analysis of clinical', 'safety data', '150']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.5.1 Efficacy', 'Updated statistical analysis methods', 'Analysis', 'for efficacy endpoints', 'Section 10.5.9.2', 'New section heading \"Additional', 'Clarification of the posterior', 'Comparative Futility Stopping Rule', 'probability calculations are added', 'Based on Bayesian Approach\"', 'added', 'Section 12.4 Adverse', 'AE reporting corrected.', 'Reporting based on CT-CAE', 'Events: Definition and', 'grading.', 'Procedures for', 'Recording, Evaluating,', 'Follow-up and', 'Reporting', 'Section 12.7.1.2', 'Additional relevant references', 'References', 'included', 'Section 12.8', 'Appendix 8 deleted', 'IMWG response criteria are', 'referenced directly. Further', 'interpretation is not needed.', '12.10 Corneal Event', 'Table 21, Table 22 and Table 23', 'Reporting based on CT-CAE', 'Severity Grading and', 'updated', 'grading.', 'Mitigation Strategy', 'Table 22 (Corneal events AE', 'grading scale) is now based on', 'best corrected visual acuity.', '151']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.12.', 'Appendix 12: Statistical Considerations for Section 10.5.9.2', 'Additional Comparative Futility Stopping Rule Based on', 'Bayesian Approach', 'Introduction', 'This document provides details about the additional comparative futility stopping rule', 'based on the Bayesian approach at interim analysis (IA) for Study 205678.', 'As described in Section 10.5.9.2, the additional comparative rule based on the Bayesian', 'approach will be used to further facilitate the decision of early stopping for futility. The', 'arm deemed inferior to the other will be dropped. In practice, if both arms pass the', 'futility boundaries based on group sequential design described above, posterior', 'probability of observing a better RR in one arm relative to the other will be calculated. If', 'such a probability is at least 90%, then the treatment arm with lower RR will be dropped', 'due to lack of efficacy. To calculate the posterior probability, a non-informative beta', 'prior (0.025,0.1) will be used for each arm.', 'Statistical Modeling', 'In the Bayesian approach,', 'let P1 denote the response rate for arm 1; m1 and X1 denote the number of participants and', 'number of responders at IA for arm 1;', 'let P2 denote the response rate for arm 2; m2 and X2 denote the number of participants and', 'number of responders at IA for arm 2;', 'We assume P1 and P2 are independent.', 'We assume the prior distributions of response rates TLy (P1) and follow a', 'beta', 'distribution beta (a,B). The beta distribution represents the prior knowledge or belief', 'R', 'about the efficacy of the new drug. The quantity reflects the prior mean response', 'rate, while the quantity a + B reflects the amount of information contained in the prior.', 'The larger value of a +B, the stronger belief the prior has. In both simulations and actual', 'IA, a non-informative beta prior (0.025,0.1) will be used for each arm.', 'We assume', 'X1/m1.P1 vbinomial (m1,P1) and X2/m2,P2', 'Consequently, the posterior distributions of the response rates P1 and P2 follow beta', 'distributions:', 'P1|x/~beta(a+ X1, B+ m1 - - X1), P2|x2~beta(a+ X2, B+ m2-x2. P1/x1 and P2/x2 are also', 'independent.', 'The comparative futility stopping rules are defined as:', '152']\n\n###\n\n", "completion": "END"}